nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ORM1—saliva—nicotine dependence	0.0423	0.123	CbGeAlD
Erlotinib—Haematochezia—Varenicline—nicotine dependence	0.0317	0.0695	CcSEcCtD
Erlotinib—Haematemesis—Varenicline—nicotine dependence	0.0184	0.0403	CcSEcCtD
Erlotinib—FLT3—cardiovascular system—nicotine dependence	0.0176	0.0513	CbGeAlD
Erlotinib—PIP4K2C—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0169	0.0839	CbGpPWpGaD
Erlotinib—Acne—Varenicline—nicotine dependence	0.0152	0.0333	CcSEcCtD
Erlotinib—Tenderness—Varenicline—nicotine dependence	0.0146	0.0321	CcSEcCtD
Erlotinib—MKNK1—cardiovascular system—nicotine dependence	0.0143	0.0416	CbGeAlD
Erlotinib—HIPK4—brain—nicotine dependence	0.0138	0.0403	CbGeAlD
Erlotinib—LTK—brain—nicotine dependence	0.0137	0.0399	CbGeAlD
Erlotinib—Musculoskeletal pain—Varenicline—nicotine dependence	0.0129	0.0284	CcSEcCtD
Erlotinib—PIP4K2C—midbrain—nicotine dependence	0.0124	0.0362	CbGeAlD
Erlotinib—ULK3—midbrain—nicotine dependence	0.0118	0.0345	CbGeAlD
Erlotinib—AURKC—brain—nicotine dependence	0.0118	0.0344	CbGeAlD
Erlotinib—Dry eye—Varenicline—nicotine dependence	0.0118	0.0259	CcSEcCtD
Erlotinib—STK10—cardiovascular system—nicotine dependence	0.0118	0.0343	CbGeAlD
Erlotinib—MKNK1—midbrain—nicotine dependence	0.0111	0.0325	CbGeAlD
Erlotinib—JAK3—brain—nicotine dependence	0.0109	0.0319	CbGeAlD
Erlotinib—EPHA6—brain—nicotine dependence	0.0109	0.0319	CbGeAlD
Erlotinib—SLK—midbrain—nicotine dependence	0.0106	0.0308	CbGeAlD
Erlotinib—MAP2K5—cardiovascular system—nicotine dependence	0.0105	0.0306	CbGeAlD
Erlotinib—PIP4K2C—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.0105	0.0522	CbGpPWpGaD
Erlotinib—PIP4K2C—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.0101	0.0501	CbGpPWpGaD
Erlotinib—Renal failure acute—Varenicline—nicotine dependence	0.01	0.022	CcSEcCtD
Erlotinib—TNK1—brain—nicotine dependence	0.01	0.0293	CbGeAlD
Erlotinib—MAP3K19—brain—nicotine dependence	0.00994	0.029	CbGeAlD
Erlotinib—Cerebrovascular accident—Varenicline—nicotine dependence	0.00947	0.0208	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00928	0.0203	CcSEcCtD
Erlotinib—Dry skin—Varenicline—nicotine dependence	0.0085	0.0186	CcSEcCtD
Erlotinib—Hypokalaemia—Varenicline—nicotine dependence	0.00844	0.0185	CcSEcCtD
Erlotinib—ABL2—brain—nicotine dependence	0.00824	0.024	CbGeAlD
Erlotinib—Gastritis—Varenicline—nicotine dependence	0.00821	0.018	CcSEcCtD
Erlotinib—MAP2K5—midbrain—nicotine dependence	0.0082	0.0239	CbGeAlD
Erlotinib—ABL1—cardiovascular system—nicotine dependence	0.0081	0.0236	CbGeAlD
Erlotinib—EGFR—brain—nicotine dependence	0.00804	0.0234	CbGeAlD
Erlotinib—Dysphagia—Varenicline—nicotine dependence	0.00802	0.0176	CcSEcCtD
Erlotinib—PIP4K2C—brain—nicotine dependence	0.00779	0.0227	CbGeAlD
Erlotinib—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00755	0.0376	CbGpPWpGaD
Erlotinib—ULK3—brain—nicotine dependence	0.00744	0.0217	CbGeAlD
Erlotinib—Infestation NOS—Varenicline—nicotine dependence	0.00715	0.0157	CcSEcCtD
Erlotinib—Infestation—Varenicline—nicotine dependence	0.00715	0.0157	CcSEcCtD
Erlotinib—Depression—Varenicline—nicotine dependence	0.00713	0.0156	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00709	0.0155	CcSEcCtD
Erlotinib—Acute coronary syndrome—Varenicline—nicotine dependence	0.00705	0.0154	CcSEcCtD
Erlotinib—Myocardial infarction—Varenicline—nicotine dependence	0.00701	0.0154	CcSEcCtD
Erlotinib—MKNK1—brain—nicotine dependence	0.007	0.0204	CbGeAlD
Erlotinib—Stomatitis—Varenicline—nicotine dependence	0.00697	0.0153	CcSEcCtD
Erlotinib—Conjunctivitis—Varenicline—nicotine dependence	0.00695	0.0152	CcSEcCtD
Erlotinib—CYP1B1—cardiovascular system—nicotine dependence	0.00686	0.02	CbGeAlD
Erlotinib—Hepatobiliary disease—Varenicline—nicotine dependence	0.00676	0.0148	CcSEcCtD
Erlotinib—Epistaxis—Varenicline—nicotine dependence	0.00674	0.0148	CcSEcCtD
Erlotinib—SLK—brain—nicotine dependence	0.00663	0.0193	CbGeAlD
Erlotinib—Urinary tract disorder—Varenicline—nicotine dependence	0.00634	0.0139	CcSEcCtD
Erlotinib—ABL1—midbrain—nicotine dependence	0.00632	0.0184	CbGeAlD
Erlotinib—Connective tissue disorder—Varenicline—nicotine dependence	0.00631	0.0138	CcSEcCtD
Erlotinib—Urethral disorder—Varenicline—nicotine dependence	0.00629	0.0138	CcSEcCtD
Erlotinib—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0062	0.0309	CbGpPWpGaD
Erlotinib—Erythema multiforme—Varenicline—nicotine dependence	0.00607	0.0133	CcSEcCtD
Erlotinib—Eye disorder—Varenicline—nicotine dependence	0.006	0.0131	CcSEcCtD
Erlotinib—Mediastinal disorder—Varenicline—nicotine dependence	0.00578	0.0127	CcSEcCtD
Erlotinib—STK10—brain—nicotine dependence	0.00577	0.0168	CbGeAlD
Erlotinib—Chills—Varenicline—nicotine dependence	0.00576	0.0126	CcSEcCtD
Erlotinib—Arrhythmia—Varenicline—nicotine dependence	0.00573	0.0126	CcSEcCtD
Erlotinib—Mental disorder—Varenicline—nicotine dependence	0.00562	0.0123	CcSEcCtD
Erlotinib—Erythema—Varenicline—nicotine dependence	0.00559	0.0122	CcSEcCtD
Erlotinib—Malnutrition—Varenicline—nicotine dependence	0.00559	0.0122	CcSEcCtD
Erlotinib—Flatulence—Varenicline—nicotine dependence	0.00551	0.0121	CcSEcCtD
Erlotinib—Back pain—Varenicline—nicotine dependence	0.0054	0.0118	CcSEcCtD
Erlotinib—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.0054	0.0269	CbGpPWpGaD
Erlotinib—MAP2K5—brain—nicotine dependence	0.00515	0.015	CbGeAlD
Erlotinib—CYP1A1—Xenobiotics—CYP2A7—nicotine dependence	0.0051	0.0254	CbGpPWpGaD
Erlotinib—Syncope—Varenicline—nicotine dependence	0.00501	0.011	CcSEcCtD
Erlotinib—Loss of consciousness—Varenicline—nicotine dependence	0.00491	0.0108	CcSEcCtD
Erlotinib—JAK3—IL4-mediated signaling events—OPRM1—nicotine dependence	0.00489	0.0243	CbGpPWpGaD
Erlotinib—Cough—Varenicline—nicotine dependence	0.00488	0.0107	CcSEcCtD
Erlotinib—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00484	0.0241	CbGpPWpGaD
Erlotinib—Arthralgia—Varenicline—nicotine dependence	0.00476	0.0104	CcSEcCtD
Erlotinib—Myalgia—Varenicline—nicotine dependence	0.00476	0.0104	CcSEcCtD
Erlotinib—Chest pain—Varenicline—nicotine dependence	0.00476	0.0104	CcSEcCtD
Erlotinib—Anxiety—Varenicline—nicotine dependence	0.00474	0.0104	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00472	0.0104	CcSEcCtD
Erlotinib—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.00468	0.0233	CbGpPWpGaD
Erlotinib—Oedema—Varenicline—nicotine dependence	0.00456	0.00999	CcSEcCtD
Erlotinib—Infection—Varenicline—nicotine dependence	0.00453	0.00993	CcSEcCtD
Erlotinib—Shock—Varenicline—nicotine dependence	0.00449	0.00983	CcSEcCtD
Erlotinib—Nervous system disorder—Varenicline—nicotine dependence	0.00447	0.0098	CcSEcCtD
Erlotinib—Thrombocytopenia—Varenicline—nicotine dependence	0.00446	0.00979	CcSEcCtD
Erlotinib—Skin disorder—Varenicline—nicotine dependence	0.00443	0.00971	CcSEcCtD
Erlotinib—Anorexia—Varenicline—nicotine dependence	0.00435	0.00953	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00415	0.00911	CcSEcCtD
Erlotinib—Insomnia—Varenicline—nicotine dependence	0.00412	0.00904	CcSEcCtD
Erlotinib—Dyspnoea—Varenicline—nicotine dependence	0.00407	0.00891	CcSEcCtD
Erlotinib—Dyspepsia—Varenicline—nicotine dependence	0.00401	0.0088	CcSEcCtD
Erlotinib—SLCO2B1—brain—nicotine dependence	0.00401	0.0117	CbGeAlD
Erlotinib—ABCG2—midbrain—nicotine dependence	0.00399	0.0116	CbGeAlD
Erlotinib—ABL1—brain—nicotine dependence	0.00397	0.0116	CbGeAlD
Erlotinib—Decreased appetite—Varenicline—nicotine dependence	0.00396	0.00869	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00394	0.00863	CcSEcCtD
Erlotinib—Fatigue—Varenicline—nicotine dependence	0.00393	0.00862	CcSEcCtD
Erlotinib—Constipation—Varenicline—nicotine dependence	0.0039	0.00855	CcSEcCtD
Erlotinib—Pain—Varenicline—nicotine dependence	0.0039	0.00855	CcSEcCtD
Erlotinib—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00384	0.0191	CbGpPWpGaD
Erlotinib—Gastrointestinal pain—Varenicline—nicotine dependence	0.00373	0.00817	CcSEcCtD
Erlotinib—ALB—brain—nicotine dependence	0.00367	0.0107	CbGeAlD
Erlotinib—Body temperature increased—Varenicline—nicotine dependence	0.0036	0.0079	CcSEcCtD
Erlotinib—Abdominal pain—Varenicline—nicotine dependence	0.0036	0.0079	CcSEcCtD
Erlotinib—CYP1B1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00344	0.0171	CbGpPWpGaD
Erlotinib—CYP1B1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0034	0.0169	CbGpPWpGaD
Erlotinib—CYP1B1—brain—nicotine dependence	0.00337	0.00981	CbGeAlD
Erlotinib—Asthenia—Varenicline—nicotine dependence	0.00327	0.00717	CcSEcCtD
Erlotinib—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00325	0.0162	CbGpPWpGaD
Erlotinib—Pruritus—Varenicline—nicotine dependence	0.00323	0.00707	CcSEcCtD
Erlotinib—Diarrhoea—Varenicline—nicotine dependence	0.00312	0.00684	CcSEcCtD
Erlotinib—ABL1—Regulation of actin dynamics for phagocytic cup formation—WASF2—nicotine dependence	0.0031	0.0154	CbGpPWpGaD
Erlotinib—MAP2K5—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00303	0.0151	CbGpPWpGaD
Erlotinib—Dizziness—Varenicline—nicotine dependence	0.00302	0.00661	CcSEcCtD
Erlotinib—ABL1—Regulation of actin dynamics for phagocytic cup formation—WASF1—nicotine dependence	0.00297	0.0148	CbGpPWpGaD
Erlotinib—Vomiting—Varenicline—nicotine dependence	0.0029	0.00635	CcSEcCtD
Erlotinib—Rash—Varenicline—nicotine dependence	0.00288	0.0063	CcSEcCtD
Erlotinib—Dermatitis—Varenicline—nicotine dependence	0.00287	0.0063	CcSEcCtD
Erlotinib—Headache—Varenicline—nicotine dependence	0.00286	0.00626	CcSEcCtD
Erlotinib—CYP1B1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00279	0.0139	CbGpPWpGaD
Erlotinib—Nausea—Varenicline—nicotine dependence	0.00271	0.00594	CcSEcCtD
Erlotinib—CYP2C8—brain—nicotine dependence	0.00258	0.00751	CbGeAlD
Erlotinib—ABCB1—cardiovascular system—nicotine dependence	0.00252	0.00734	CbGeAlD
Erlotinib—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00251	0.0125	CbGpPWpGaD
Erlotinib—ABCG2—brain—nicotine dependence	0.00251	0.00731	CbGeAlD
Erlotinib—CYP1A1—brain—nicotine dependence	0.00238	0.00694	CbGeAlD
Erlotinib—ABL1—Fcgamma receptor (FCGR) dependent phagocytosis—WASF2—nicotine dependence	0.00234	0.0117	CbGpPWpGaD
Erlotinib—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00224	0.0112	CbGpPWpGaD
Erlotinib—ABL1—Fcgamma receptor (FCGR) dependent phagocytosis—WASF1—nicotine dependence	0.00224	0.0112	CbGpPWpGaD
Erlotinib—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00221	0.011	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—FGD1—nicotine dependence	0.00218	0.0109	CbGpPWpGaD
Erlotinib—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00212	0.0106	CbGpPWpGaD
Erlotinib—CYP1A1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00209	0.0104	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00197	0.00982	CbGpPWpGaD
Erlotinib—ABCB1—midbrain—nicotine dependence	0.00197	0.00573	CbGeAlD
Erlotinib—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00194	0.00968	CbGpPWpGaD
Erlotinib—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00192	0.00955	CbGpPWpGaD
Erlotinib—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00182	0.00906	CbGpPWpGaD
Erlotinib—CYP1A1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00172	0.00856	CbGpPWpGaD
Erlotinib—CYP2D6—brain—nicotine dependence	0.00172	0.00501	CbGeAlD
Erlotinib—UGT1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00169	0.00839	CbGpPWpGaD
Erlotinib—ABL1—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00165	0.00823	CbGpPWpGaD
Erlotinib—EGFR—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00162	0.00809	CbGpPWpGaD
Erlotinib—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0016	0.00794	CbGpPWpGaD
Erlotinib—UGT1A1—Biological oxidations—CYP2A7—nicotine dependence	0.00159	0.00791	CbGpPWpGaD
Erlotinib—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00158	0.00784	CbGpPWpGaD
Erlotinib—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00157	0.00784	CbGpPWpGaD
Erlotinib—CYP1B1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00157	0.00783	CbGpPWpGaD
Erlotinib—UGT1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00157	0.0078	CbGpPWpGaD
Erlotinib—CYP1B1—Biological oxidations—CYP2A7—nicotine dependence	0.00148	0.00738	CbGpPWpGaD
Erlotinib—CYP1B1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00146	0.00728	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00137	0.0068	CbGpPWpGaD
Erlotinib—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00135	0.00673	CbGpPWpGaD
Erlotinib—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00133	0.00664	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—CCAR1—nicotine dependence	0.00133	0.0066	CbGpPWpGaD
Erlotinib—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00129	0.00644	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—TAS2R16—nicotine dependence	0.00124	0.00618	CbGpPWpGaD
Erlotinib—ABCB1—brain—nicotine dependence	0.00124	0.0036	CbGeAlD
Erlotinib—EGFR—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00123	0.00611	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00118	0.00586	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FGD1—nicotine dependence	0.00117	0.00583	CbGpPWpGaD
Erlotinib—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0011	0.00546	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—FGD1—nicotine dependence	0.00107	0.00534	CbGpPWpGaD
Erlotinib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00104	0.00519	CbGpPWpGaD
Erlotinib—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00103	0.00513	CbGpPWpGaD
Erlotinib—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00102	0.0051	CbGpPWpGaD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00101	0.00505	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—FGD1—nicotine dependence	0.000973	0.00485	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TAS2R16—nicotine dependence	0.000972	0.00484	CbGpPWpGaD
Erlotinib—CYP1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000968	0.00482	CbGpPWpGaD
Erlotinib—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.000966	0.00481	CbGpPWpGaD
Erlotinib—MKNK1—Disease—AKR1B10—nicotine dependence	0.000962	0.00479	CbGpPWpGaD
Erlotinib—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000953	0.00474	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—CYP2A7—nicotine dependence	0.000913	0.00454	CbGpPWpGaD
Erlotinib—CYP1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0009	0.00448	CbGpPWpGaD
Erlotinib—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000888	0.00442	CbGpPWpGaD
Erlotinib—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000845	0.00421	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.000837	0.00417	CbGpPWpGaD
Erlotinib—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000825	0.00411	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FGD1—nicotine dependence	0.000762	0.0038	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TAS2R16—nicotine dependence	0.000733	0.00365	CbGpPWpGaD
Erlotinib—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000729	0.00363	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000687	0.00342	CbGpPWpGaD
Erlotinib—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000677	0.00337	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKR1B10—nicotine dependence	0.000673	0.00335	CbGpPWpGaD
Erlotinib—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000617	0.00307	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TAS2R16—nicotine dependence	0.000597	0.00297	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000582	0.0029	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—OPRM1—nicotine dependence	0.000576	0.00287	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FGD1—nicotine dependence	0.000575	0.00286	CbGpPWpGaD
Erlotinib—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000574	0.00286	CbGpPWpGaD
Erlotinib—JAK3—Immune System—WASF2—nicotine dependence	0.000553	0.00276	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TAS2R16—nicotine dependence	0.000543	0.0027	CbGpPWpGaD
Erlotinib—JAK3—Immune System—WASF1—nicotine dependence	0.000531	0.00264	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—OPRM1—nicotine dependence	0.000523	0.0026	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKR1B10—nicotine dependence	0.000508	0.00253	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000492	0.00245	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—WASF2—nicotine dependence	0.000486	0.00242	CbGpPWpGaD
Erlotinib—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000476	0.00237	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—WASF2—nicotine dependence	0.000474	0.00236	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FGD1—nicotine dependence	0.000469	0.00233	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—WASF1—nicotine dependence	0.000466	0.00232	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—WASF1—nicotine dependence	0.000455	0.00227	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000449	0.00224	CbGpPWpGaD
Erlotinib—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000443	0.00221	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—FGD1—nicotine dependence	0.000426	0.00212	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—DRD2—nicotine dependence	0.000416	0.00207	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—WASF2—nicotine dependence	0.000416	0.00207	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKR1B10—nicotine dependence	0.000414	0.00206	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—OPRM1—nicotine dependence	0.00041	0.00204	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—WASF1—nicotine dependence	0.000398	0.00198	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—DRD2—nicotine dependence	0.000378	0.00188	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—WASF2—nicotine dependence	0.000358	0.00178	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—WASF1—nicotine dependence	0.000343	0.00171	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TAS2R16—nicotine dependence	0.00032	0.0016	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKR1B10—nicotine dependence	0.000317	0.00158	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—OPRM1—nicotine dependence	0.000309	0.00154	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000304	0.00151	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—DRD2—nicotine dependence	0.000296	0.00147	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—WASF2—nicotine dependence	0.000292	0.00145	CbGpPWpGaD
Erlotinib—ABL1—Immune System—WASF2—nicotine dependence	0.000283	0.00141	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—WASF1—nicotine dependence	0.00028	0.00139	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CYP2A7—nicotine dependence	0.000272	0.00135	CbGpPWpGaD
Erlotinib—ABL1—Immune System—WASF1—nicotine dependence	0.000272	0.00135	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000266	0.00133	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CYP2A7—nicotine dependence	0.000253	0.00126	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—OPRM1—nicotine dependence	0.000252	0.00125	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGD1—nicotine dependence	0.000251	0.00125	CbGpPWpGaD
Erlotinib—EGFR—Immune System—WASF2—nicotine dependence	0.000242	0.00121	CbGpPWpGaD
Erlotinib—EGFR—Immune System—WASF1—nicotine dependence	0.000232	0.00116	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP2A7—nicotine dependence	0.000231	0.00115	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—OPRM1—nicotine dependence	0.000229	0.00114	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—DRD2—nicotine dependence	0.000223	0.00111	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKR1B10—nicotine dependence	0.000222	0.00111	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—DRD2—nicotine dependence	0.000182	0.000906	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—DRD2—nicotine dependence	0.000165	0.000823	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000165	0.000823	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—WASF2—nicotine dependence	0.000157	0.000779	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP2A7—nicotine dependence	0.000156	0.000777	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—WASF1—nicotine dependence	0.00015	0.000747	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000143	0.000713	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP2A7—nicotine dependence	0.000142	0.000709	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—OPRM1—nicotine dependence	0.000135	0.000673	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000125	0.000621	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000117	0.000585	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2A7—nicotine dependence	9.95e-05	0.000496	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD2—nicotine dependence	9.77e-05	0.000486	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2A7—nicotine dependence	7.68e-05	0.000382	CbGpPWpGaD
